Iranian Society of Gynecology Oncology

Document Type : Original Research Article


1 Vali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Gynecology and Obstetrics, Nekooi Hospital, Qom University of Medical Science and Health Services, Qom, Iran


Background & Objective: Preserving fertility in women with cancer before therapeutic interventions is very important. This study was evaluating the 8 years’ experience of an onco-fertility center from 2013 to 2020 on fertility preservation and its outcomes in female cancer survivors.
Materials & Methods: Participants were females with an approved cancer diagnosis of reproductive ages that were referred for fertility preservation. After proper counseling by an expert team, the final decision on the fertility preservation method was made based on the patient's condition and survival expectation. The primary goal was to collect data about the fertility, clinical and survival outcomes of these women and pregnancy rate as a secondary objective that were compared between cancer types.
Results: Totally 337 participants were recruited with a mean±SD age of 30.7±6.6 years. Gynecological cancers accounted for 166 (49.3%) of all cases followed by breast (107 (31.8%)) and other cancers (64 (19.0%)) respectively. Of those, 144 (42.7%) cases entered into the ovulation induction cycle and the others did not continue due to lack of correct information and late referral, and inability to postpone treatment as the major reasons. Comparing between 3 groups (gynecological, breast and other cancers), a higher rate of pregnancy otherwise not statistically different was detected in gynecological cancer survivors. In the breast cancer survivors, the chance of oocyte retrieval and fertility was not lower than in other cancers.
Conclusion: Many patients and even their therapists are unfamiliar with the methods of fertility preservation, and when they consider it, the golden time is usually passed. Therefore, having a good consultation with the survivors and patient education may be the most important issue that led to a timely referral for preserving fertility in cancer patients.


Main Subjects

1. Shah DK, Goldman E, Fisseha S. Medical, ethical, and legal considerations in fertility preservation. Int J Gynaecol Obstet. 2011;115(1):11-5. [DOI:10.1016/j.ijgo.2011.05.011] [PMID]
2. Sigismondi C, Papaleo E, Vigano P, Vailati S, Candiani M, Ottolina J, et al. Fertility preservation in female cancer patients: a single center experience. Chin J Cancer. 2015;34(1):56-60. [DOI:10.5732/cjc.014.10252] [PMID] [PMCID]
3. Oktay K, Harvey BE, Loren AW. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary. J Oncol Pract. 2018;14(6):381-5. [DOI:10.1200/JOP.18.00160] [PMID]
4. Schmidt K, Larsen E, Andersen C, Andersen A. Risk of ovarian failure and fertility preserving methods in girls and adolescents with a malignant disease. Int J Gynaecol Obstet. 2010;117(2):163-74. [DOI:10.1111/j.1471-0528.2009.02408.x] [PMID]
5. Bastings L, Baysal O, Beerendonk CC, Braat DD, Nelen WL. Referral for fertility preservation counselling in female cancer patients. Hum Reprod. 2014;29(10):2228-37. [DOI:10.1093/humrep/deu186] [PMID]
6. Linkeviciute A, Boniolo G, Chiavari L, Peccatori FA. Fertility preservation in cancer patients: The global framework. Cancer Treat Rev. 2014;40(8):1019-27. [DOI:10.1016/j.ctrv.2014.06.001] [PMID]
7. Gordhandas S, Stewart J, Shah N, Wahmann B, Schattman G, Rosenwaks Z. Utilization and knowledge of oncofertility preservation services: a single institution experience. Fertil Steril. 2019;111(4):39-40. [DOI:10.1016/j.fertnstert.2019.02.096]
8. Walsh SK, Ginsburg ES, Lehmann LS, Partridge AH. Oncofertility: Fertile Ground for Conflict Between Patient Autonomy and Medical Values. Oncologist. 2017;22(7):860-3. [DOI:10.1634/theoncologist.2016-0373] [PMID] [PMCID]
9. Dursun P, Dogan NU, Ayhan A. Oncofertility for gynecologic and non-gynecologic cancers: Fertility sparing in young women of reproductive age. Crit Rev Oncol Hematol. 2014;92(3):258-67. [DOI:10.1016/j.critrevonc.2014.07.001] [PMID]
10. Goncalves V, Travado L, Ferreira PL, Quinn G. Protocol for the development and acceptability of a fertility-related decision aid for young women with breast cancer in Portugal. BMJ Open. 2019;9(7):e030690. [DOI:10.1136/bmjopen-2019-030690] [PMID] [PMCID]
11. Lee S, Ozkavukcu S, Heytens E, Moy F, Oktay K. Value of Early Referral to Fertility Preservation in Young Women With Breast Cancer. J Clin Oncol. 2010;28(31):4683-6. [DOI:10.1200/JCO.2010.30.5748] [PMID] [PMCID]
12. Donnez J DM. Ovarian tissue freezing: current status. Curr Opin Obstet Gynecol. 2015;27(3):222-30. [DOI:10.1097/GCO.0000000000000171] [PMID]
13. Loren AW MP, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K, American Society of Clinical Oncology. Fertility Preservation for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2013;31(19):2500-10. [DOI:10.1200/JCO.2013.49.2678] [PMID] [PMCID]
14. Austin G Armstrong BFK, Brigid M Smith, Teresa K Woodruff, Mary Ellen Pavone, and Francesca E Duncan. Ovarian tissue cryopreservation in young females through the Oncofertility Consortium's National Physicians Cooperative. Future Oncol. 2018;14(4):363-72. [DOI:10.2217/fon-2017-0410] [PMID] [PMCID]
15. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet. 1999;354(9190):1586-90. [DOI:10.1016/S0140-6736(99)05203-4] [PMID]
16. Azim AA, Costantini-Ferrando M, Oktay K. Safety of Fertility Preservation by Ovarian Stimulation With Letrozole and Gonadotropins in Patients With Breast Cancer: A Prospective Controlled Study. J Clin Oncol. 2008;26(16):2630-5. [DOI:10.1200/JCO.2007.14.8700] [PMID]
17. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA, Jr., Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14(1):1-6. [DOI:10.1186/s12916-015-0545-7] [PMID] [PMCID]
18. Rashidi BH, Tehrani ES, Ghaffari F. Ovarian stimulation for emergency fertility preservation in cancer patients: A case series study. Gynecol Oncol Rep. 2014;10:19-21. [DOI:10.1016/j.gore.2014.08.002] [PMID] [PMCID]
19. Barley MH, Turner NJ, Goodacre R. Recommendations on the Implementation of Genetic Algorithms for the Directed Evolution of Enzymes for Industrial Purposes. Chembiochem. 2017;18(12):1087-97. [DOI:10.1002/cbic.201700013] [PMID]
20. Klock SC, Zhang JX, Kazer RR. Fertility preservation for female cancer patients: early clinical experience. Fertil Steril. 2010;94(1):149-55. [DOI:10.1016/j.fertnstert.2009.03.028] [PMID]
21. Agarwal A, Said TM. Implications of systemic malignancies on human fertility. Reprod Biomed Online. 2004;9(6):673-9. [DOI:10.1016/S1472-6483(10)61779-8] [PMID]
22. Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril. 2012;97(1):125-33. [DOI:10.1016/j.fertnstert.2011.10.014] [PMID]
23. Domingo J, Guillen V, Ayllon Y, Martinez M, Munoz E, Pellicer A, et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril. 2012;97(4):930-4. [DOI:10.1016/j.fertnstert.2012.01.093] [PMID]
24. Turan V, Quinn MM, Dayioglu N, Rosen MP, Oktay K. The impact of malignancy on response to ovarian stimulation for fertility preservation: a meta-analysis. Fertil Steril. 2018;110(7):1347-55. [DOI:10.1016/j.fertnstert.2018.08.013] [PMID]
25. Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer. J Clin Oncol. 2015;33(22):2424-9. [DOI:10.1200/JCO.2014.59.3723] [PMID] [PMCID]
26. Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 Mutations With Occult Primary Ovarian Insufficiency: A Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks. J Clin Oncol. 2010;28(2):240-4. [DOI:10.1200/JCO.2009.24.2057] [PMID] [PMCID]
27. Wang ET, Pisarska MD, Bresee C, Chen YD, Lester J, Afshar Y, et al. BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertil Steril. 2014;102(6):1723-8. [DOI:10.1016/j.fertnstert.2014.08.014] [PMID] [PMCID]
28. Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172):172ra21. [DOI:10.1126/scitranslmed.3004925] [PMID] [PMCID]
29. Johnson L, Sammel MD, Domchek S, Schanne A, Prewitt M, Gracia C. Antimüllerian hormone levels are lower in BRCA2 mutation carriers. Fertil Steril. 2017;107(5):1256-65. [DOI:10.1016/j.fertnstert.2017.03.018] [PMID] [PMCID]
30. Ge W, Clendenen TV, Afanasyeva Y, Koenig KL, Agnoli C, Brinton LA, et al. Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts. Int J Cancer. 2018;142(11):2215-26. [DOI:10.1002/ijc.31249] [PMID] [PMCID]
31. Mahajan N. Fertility preservation in female cancer patients: An overview. J Hum Reprod Sci. 2015;8(1):3-13. [DOI:10.4103/0974-1208.178632] [DOI:10.4103/0974-1208.153119]
32. Turan V, Bedoschi G, Emirdar V, Moy F, Oktay K. Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes. Reprod Sci. 2018;25(1):26-32. [DOI:10.1177/1933719117728800] [PMID]
33. Quinn MM, Cakmak H, Letourneau JM, Cedars MI, Rosen MP. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. 2017;32(3):568-74. [DOI:10.1093/humrep/dew355] [PMID]
34. Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et al. Letrozole Reduces Estrogen and Gonadotropin Exposure in Women with Breast Cancer Undergoing Ovarian Stimulation before Chemotherapy. J Clin Endocrinol Metab. 2006;91(10):3885-90. [DOI:10.1210/jc.2006-0962] [PMID]
35. Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673-80. [DOI:10.1016/j.fertnstert.2013.07.1992] [PMID]
36. Rodriguez-Wallberg KA, Oktay K. Fertility preservation in women with breast cancer. Clin Obstet Gynecol. 2010;53(4):753-62. [DOI:10.1097/GRF.0b013e3181f96e00] [PMID] [PMCID]
37. Revel A, Revel-Vilk S. Fertility preservation in young cancer patients. J Hum Reprod Sci. 2010;3(1):2-7. [DOI:10.4103/0974-1208.63113] [PMID] [PMCID]
38. Harzif AK, Santavi, V.P., Maidarti, M., Viveko, B. Investigation of Each Society for Fertility Preservation in Asia. Front Endocrinol. 2019;10:151. [DOI:10.3389/fendo.2019.00151] [PMID] [PMCID]
39. Pennings G MH. Ethical issues in infertility treatment. Best Pract Res Clin Obstet Gynaecol. 2012;26(6):853-63. [DOI:10.1016/j.bpobgyn.2012.04.002] [PMID]
40. Garvelink MM tKM, Bakker RM, Geense WJ, Jenninga E, Louwé LA, Hilders CG, Stiggelbout AM. Women's experiences with information provision and deciding about fertility preservation in the Netherlands: 'satisfaction in general, but unmet needs'. Health Expect. 2015;18(5):956-67. [DOI:10.1111/hex.12068] [PMID] [PMCID]
41. Moravek MB CR, Smith KN, Kazer RR, Klock SC, Lawson AK, Gradishar WJ, Pavone ME. Long-term outcomes in cancer patients who did or did not pursue fertility preservation. Fertil Steril. 2018;109(2):349-55. [DOI:10.1016/j.fertnstert.2017.10.029] [PMID] [PMCID]
42. Hammarberg K, Kirkman M, Stern C, McLachlan RI, Clarke G, Agresta F, et al. Survey of Reproductive Experiences and Outcomes of Cancer Survivors Who Stored Reproductive Material Before Treatment. Hum Reprod. 2017;32(12):2423-30. [DOI:10.1093/humrep/dex314] [PMID]